A small feasibility study (n = 15, with nine patients unmethylated) reported a median OS of 19.3 months in newly diagnosed GBM treated with first-line adjuvant anti-PD-1 plus anti-CTLA-4, followed by standard radiotherapy34. Here, CTLA4 is linked to glioblastoma.